News & Events about Curevac.
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 7, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends...
CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolioThe company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 31...
Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and fluCOVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65Flu...
Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside. CureVac stock could gain close to 100% On Thursday, Eliana Merle turned bullish on the biopharmaceutical firm and sharply increased her price ...